# Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

> **NCT02210117** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 104 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Kidney Carcinoma
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biopsy
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Metastasectomy
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02210117
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-11-25
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210117, "Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02210117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*